Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2023 Jan;82(1):e24.
doi: 10.1136/annrheumdis-2020-219329. Epub 2021 Feb 4.

Response to: 'Correspondence on 'Rituximab as therapy to induce remission after relapse in ANCA-associated vasculitis'' by Parikh et al

Rona M Smith  1   2 , Peter A Merkel  3 , David Jayne  4   2
Affiliations
Free article
Comment

Response to: 'Correspondence on 'Rituximab as therapy to induce remission after relapse in ANCA-associated vasculitis'' by Parikh et al

Rona M Smith et al. Ann Rheum Dis. 2023 Jan.
Free article
No abstract available

Keywords: B-lymphocytes; granulomatosis with polyangiitis; rituximab; systemic vasculitis.

PubMed Disclaimer

Conflict of interest statement

Competing interests: RMS reports grants from Roche during the conduct of the study. PM reports personal fees from AbbVie, grants and personal fees from AstraZeneca, personal fees from Biogen, grants and personal fees from Bristol-Myers Squibb, grants and personal fees from Boeringher-Ingelheim, grants and personal fees from Celgene, grants and personal fees from ChemoCentryx, CSL Behring, grants and personal fees from Genentech/Roche, grants and personal fees from Genzyme/Sanofi, grants and personal fees from GlaxoSmithKline, grants and personal fees from InflaRx, personal fees from Insmed, personal fees from Jannsen, personal fees from Kiniksa, grants from Kypha, personal fees from Sparrow, grants from TerumoBCT outside the submitted work. DJ reports grants from Roche/Genentech, during the conduct of the study; grants from Sanofi-Genzyme, grants and personal fees from Chemocentryx, grants and personal fees from GSK, grants from Roche/Genentech, personal fees from Takeda, personal fees from Insmed, personal fees from Astra-Zeneca, personal fees from Infla-RX, personal fees from Chugai, personal fees from Boehringer-Ingelheim outside the submitted work.

Comment on

  • Rituximab as therapy to induce remission after relapse in ANCA-associated vasculitis.
    Smith RM, Jones RB, Specks U, Bond S, Nodale M, Aljayyousi R, Andrews J, Bruchfeld A, Camilleri B, Carette S, Cheung CK, Derebail V, Doulton T, Forbess L, Fujimoto S, Furuta S, Gewurz-Singer O, Harper L, Ito-Ihara T, Khalidi N, Klocke R, Koening C, Komagata Y, Langford C, Lanyon P, Luqmani RA, Makino H, McAlear CA, Monach P, Moreland LW, Mynard K, Nachman P, Pagnoux C, Pearce F, Peh CA, Pusey C, Ranganathan D, Rhee RL, Spiera R, Sreih AG, Tesar V, Walters G, Weisman MH, Wroe C, Merkel PA, Jayne D; RITAZAREM coinvestigators; RITAZAREM co-investigators. Smith RM, et al. Ann Rheum Dis. 2020 Sep;79(9):1243-1249. doi: 10.1136/annrheumdis-2019-216863. Epub 2020 Jun 24. Ann Rheum Dis. 2020. PMID: 32581088 Free PMC article.
  • Correspondence on 'Rituximab as therapy to induce remission after relapse in ANCA-associated vasculitis'.
    Parikh A, Devarasetti PK, Rajasekhar L. Parikh A, et al. Ann Rheum Dis. 2023 Jan;82(1):e23. doi: 10.1136/annrheumdis-2020-219312. Epub 2021 Feb 4. Ann Rheum Dis. 2023. PMID: 33542103 No abstract available.

MeSH terms

Substances

LinkOut - more resources